Share on StockTwits

Research analysts at MKM Partners lifted their price target on shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) from $28.00 to $38.00 in a report released on Tuesday. The firm currently has a “buy” rating on the stock. MKM Partners’ price target would indicate a potential upside of 31.31% from the company’s current price.

Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded down 0.41% during mid-day trading on Tuesday, hitting $28.82. 13,795 shares of the company’s stock traded hands. BioSpecifics Technologies Corp. has a 1-year low of $17.21 and a 1-year high of $28.95. The stock’s 50-day moving average is $26.81 and its 200-day moving average is $25.60. The company has a market cap of $184.3 million and a price-to-earnings ratio of 42.62.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) last issued its quarterly earnings data on Monday, August 11th. The company reported $0.09 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.12 by $0.03. The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $2.91 million. On average, analysts predict that BioSpecifics Technologies Corp. will post $0.81 earnings per share for the current fiscal year.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.